Patent ID: 8361730

Claim:
A method for determining the severity of an inflammatory disease comprising: (a) contacting a fluid sample comprising blood cells from a subject with at least two toll-like receptor (TLR) ligands in vitro; (b) determining in the fluid sample concentrations of at least two proteins relevant to inflammatory disease; and (c) comparing the concentrations of the proteins relevant to inflammatory disease to control concentrations of the proteins relevant to inflammatory disease, wherein a statistically significant similarity of the sample to the control is indicative of a particular stage of the inflammatory disease, wherein the at least two proteins relevant to inflammatory disease are selected from the group consisting of IGF-1, IL-1 ra, ICAM-1, SHBG, MMP-3, Apolipoprotein A1, IgM, MIP-1beta, TIMP-1, Calcitonin, IgA, IL-16, Carcinoembryonic Antigen, Factor VII, Glutathione S-Transferase, IL-12p70, TGF-alpha, MCP-1, Eotaxin, TNF-beta, Beta-2 Microglobulin, CD40, VEGF, Cancer antigen 19-9, VCAM-1, Growth Hormone, Insulin, Myeloperoxidase, Endothelin-1, IL-15, IL-7, Apolipoprotein CIII, MMP-2, Ferritin, MMP-9, FGF Basic, G-CSF, Thyroid Stimulating Hormone, CD40 Ligand, Stem Cell Factor, Brain-Derived Neurotrophic Factor, Complement 3, IFN-gamma, Apolipoprotein H, Myoglobin, IL-1 alpha, OSM (Oncostatin M), RANTES, EGF, ENA-78, Alpha-Fetoprotein, Thyroxine Binding Globulin, IL-8, Thrombospondin-1, Creatine Kinase-MB, IL-17, Fatty Acid Binding Protein, IL-6, IL-12p40, IL-23, TNF RII, Haptoglobin, IgE, Lipoprotein (a), Free Prostate Specific Antigen, Fibrinogen, Alpha-1 Antitrypsin, C Reactive Protein, IL-4, IL-10, Erythropoietin, Adiponectin, Serum Amyloid P, Lymphotactin, IL-2, GM-CSF, IL-3, Tissue Factor, Thrombopoietin, EN-RAGE, SGOT, Leptin, PAI-1, MDC, Prostatic Acid Phosphatase, IL-1beta, MIP-1alpha, Epiregulin, IL-17E, IL-5, Amphiregulin, Cancer Antigen 125, PAPP-A, IL-13, Von Willebrand Factor, IL-18, or Alpha-2 Macroglobulin.